TABLE 2.
Gene expression analysis of ALOX15, CLC, CYSLTR2, HRH4 and SMPD3
| Patients | |||||
|---|---|---|---|---|---|
| HCs | Total | Asthma | Asthma +CRSwNP | N-ERD | |
| ALOX15 | 1.88±1.51 | 10.95±9.04* | 10.35±8.63* | 13.22±10.60* | 9.28±7.29* |
| CLC | 2.21±1.43 | 10.87±12.06* | 8.49±11.72* | 11.13±10.86* | 16.92±13.02*,# |
| CYSLTR2 | 2.83±1.13 | 8.05±4.44* | 7.59±4.58* | 8.41±4.28* | 8.75±4.33* |
| HRH4 | 1.78±0.98 | 4.43±2.63* | 3.83±2.68* | 5.28±2.33*,# | 4.81±2.61* |
| SMPD3 | 2.44±1.34 | 11.99±13.58* | 12.38±16.83* | 11.63±7.70* | 11.44±10.59* |
Gene expression values (mean±sd) determined by quantitative PCR (2-ΔΔCt). Data were analysed by ANOVA and post hoc test or Kruskal–Wallis analysis. Only statistically significant differences are indicated after adjustment by sex, age and atopy. HC: healthy control; CRSwNP: chronic rhinosinusitis with nasal polyposis; N-ERD: nonsteroidal anti-inflammatory drug-exacerbated respiratory disease. *: p<0.05 compared to HCs; #: p<0.05 compared to the asthma group.